The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients ...

The government asserted that Biohaven’s fraud stopped in October 2022, when Pfizer acquired the company and terminated the Nurtec speaker programmes. "We are pleased to put this legacy matter ...

World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (Biohaven ...

Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven. "Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical ...

Jan. 14, 2025 — Painful skin and trouble sleeping are among the problems reported when tapering cortisone cream for atopic eczema, according to a new study. Many users consider the problems to ...

Nebraska will receive $62,688.71. Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine medication. The company also paid some ...